Antitumor activity of G3139 lipid nanoparticles (LNPs)

Xiaogang Pan, Li Chen, Shujun Liu, Xiaojuan Yang, Jian Xin Gao, Robert J. Lee

Research output: Contribution to journalArticlepeer-review

32 Scopus citations


G3139, an antisense oligodeoxyribonucleotide (ODN) against Bcl-2, contains two CpG dinucleotides and has shown Immunostimulatory activities in preclinical studies. It has been suggested that immunoactivation, rather than antisense activity, is primarily responsible for the therapeutic efficacy of G3139. Nanoparticle formulations naturally target phagocytic antigen presenting cells and therefore might enhance the immunological effects of G3139. In this study, a novel formulation of lipid nanoparticles (LNPs) encapsulating G3139 was synthesized and evaluated in mice bearing L1210 subcutaneous tumors. Intravenous injection of G3139-LNPs into mice led to increased serum levels of IL-6 and IFN-γ, promoted proliferation of natural killer (NK) cells and dendritic cells (DCs), and triggered a strong antitumor immune response in mice. The observed effects were much greaterthan those induced by free G3139. Correspondingly, the G3139-LNPs more effectively inhibited tumor growth and induced complete tumor regression in some mice. In contrast, free G3139 was ineffective in tumor growth inhibition and did not prolong survival of the tumor-bearing mice. These results suggest that G3139-LNPs are a potential immunomodulatory agent and may have applications in cancer therapy.

Original languageEnglish (US)
Pages (from-to)211-220
Number of pages10
JournalMolecular pharmaceutics
Issue number1
StatePublished - Feb 2 2009
Externally publishedYes


  • Cancer
  • CpG motif
  • G3139
  • Immunotherapy
  • Lipid nanoparticles
  • Oligodeoxyribonucleotide

Fingerprint Dive into the research topics of 'Antitumor activity of G3139 lipid nanoparticles (LNPs)'. Together they form a unique fingerprint.

Cite this